A retrospective observational study of 219 patients with COVID-19 found that 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. Patients with new-onset cerebrovascular disease (CVD) were significantly older, more likely to have severe COVID-19, and had more cardiovascular risk factors, including hypertension, diabetes, and a history of CVD. They also had higher inflammatory responses and hypercoagulable states, as indicated by elevated C-reactive protein and D-dimer levels. Of the 10 patients with ischaemic stroke, 6 received antiplatelet treatment and 3 died, while 4 received anticoagulant treatment and 2 died. The overall mortality rate for CVD patients was 54.5%. The study suggests that older patients with risk factors are more likely to develop CVD, which is an important negative prognostic factor. The development of CVD following COVID-19 may be related to the prothrombotic effects of the inflammatory response. The study highlights the importance of monitoring and managing cardiovascular risk factors in older patients with severe COVID-19. The findings indicate that CVD is not uncommon in patients with COVID-19 and that further research is needed to identify optimal management strategies. The study has limitations, including a small sample size and the lack of data on asymptomatic cases. The results emphasize the need for early intervention to prevent the progression of CVD in patients with COVID-19.A retrospective observational study of 219 patients with COVID-19 found that 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. Patients with new-onset cerebrovascular disease (CVD) were significantly older, more likely to have severe COVID-19, and had more cardiovascular risk factors, including hypertension, diabetes, and a history of CVD. They also had higher inflammatory responses and hypercoagulable states, as indicated by elevated C-reactive protein and D-dimer levels. Of the 10 patients with ischaemic stroke, 6 received antiplatelet treatment and 3 died, while 4 received anticoagulant treatment and 2 died. The overall mortality rate for CVD patients was 54.5%. The study suggests that older patients with risk factors are more likely to develop CVD, which is an important negative prognostic factor. The development of CVD following COVID-19 may be related to the prothrombotic effects of the inflammatory response. The study highlights the importance of monitoring and managing cardiovascular risk factors in older patients with severe COVID-19. The findings indicate that CVD is not uncommon in patients with COVID-19 and that further research is needed to identify optimal management strategies. The study has limitations, including a small sample size and the lack of data on asymptomatic cases. The results emphasize the need for early intervention to prevent the progression of CVD in patients with COVID-19.